Conventional glioblastoma treatment still gives very modest results, thus development of the new treatment modalities is desperately needed for these disease.The present study was aimed at analyzing the effect of bradykinin (BK) antagonists on proliferation of the human glioblastoma cells U373. Methods. MTT-based cell proliferation assay. Results. BKM-570 revealed a significant antiproliferative activity in the U373 cells with LC
Introduction. Glioblastoma is the most common and lethal form of the central nervous system tumors, and is known to be highly therapy resistant. Development of the new treatment modalities is desperately needed for these diseases.
Nonapeptide bradykinin (BK) is known to stimulate cancer cells growth [1] as well as their migration and invasion by inducing the activity of matrix metalloprotease (MMP) [2] . BK is linked to the formation of new blood vessels by stimulating the release of vascular endothelial growth factor (VEGF) [2] . These activities operate together to promote strongly the growth and invasive properties of certain tumor types, especially gliomas, thereby place BK in an ideal position for the generating of anti-cancer drugs.
The BK antagonists with impressive inhibition of the human cancer cell lines and the mouse tumor xenograt growth have been developed [3] . Despite the intensive study of these compounds, there are no published data about their testing on the glioblastoma cell lines. Recently, it has been shown that BK acts through a bradykinin receptor 2 (B2R) as a chemoattractant guiding the glioma cells toward blood vessels in the rat brain slices [4] .
Thus, B2R antagonist emerges as an attractive therapeutic agent for glioma patients.
It has been reported that anti-angiogenesis and antimatrix metalloproteases (MMP) activities are important components of the excellent in vivo anti-cancer activity of BK anatagonists. These substances offer advantages of combination therapy in one compound. These promising multitargeted anti-cancer compounds selectively stimulate apoptosis in cancers and also inhibit both angiogenesis and MMP action in treated lung and prostate tumors in nude mice.
Here we present that the BK antagonist BKM-570 possesses a high antiproliferative activity in the human glioblastoma cells U373. The obtained results demonst-rate that BKM-570 exhibits the anti-cancer activity. This work forms a basis for the pre-clinical studies using animal models for the evaluation of these compounds as new anti-cancer drugs.
Materials and methods. Cell proliferation assay. The U373 cells (obtained from R. E. Kavetskogo Institute of experimental pathology, oncology and radiobiology, NAS of UkraineU) were seeded in triplicates into 96 well plates at density 3 × 10 3 cells/well and were grown in complete DMEM («PAA», Germany) in an environment of 95 % air/5 % CO 2 .
The drugs were applied at final concentration of 0.01, 0.1, 1, 10, and 100 µM, which were reached by a serial dilution method. The cell proliferation was measured using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) («Sigma», USA) after 72 h of cultivation.
Results and discussion. The cancer cells are characterized by an increased proliferation rate. To analyze the antiproliferative effect of the BK antagonists, we used the human glioblastoma cells U373. The MTT assay was employed to determine the growth-suppression effect of the tested compounds.
Based on the cytotoxicity test data, the LC 50 parameter was calculated (molar concentration of compound leading to 50 % cell death as compared to a control group treated with DMSO).
The non-peptide BK antagonist BKM-570 and its derivative BKM-1800 were enrolled in this study. It was found that BKM-570 revealed a significant growth suppressor activity in the U373 cells in dose-dependent manner after the addition to the culture medium (Figure, A) . LC 50 of BKM-570 was 3,8 mM, while LC 50 of BKM-1800 was 25,8 mM.
The obtained results were in accordance with those previously described by Stewart et al. [5] : BKM-570 was the leader compound both in vitro (LC 50 1,8 mM on the small-cell lung cancer (SCLC) cells) and in vivo (91 % inhibition of the tumor xenograf growth in mice). Our assays revealed much lower activity of BKM-1800, in contrast to the data published previously by Gera et al. (LC 50 1,7 mM on the SCLC cells in vitro and 78 % of PC3 prostate cancer growth inhibition in vivo) [6] .
Thus, the cytotoxic activity of these compounds seems to depend on the specificity of each cell line tested.
Conclusions. In summary, we have shown that BKM-570 represses the glioblastoma cells growth and is a promising compound for the in vivo studies as a potential anti-cancer agent. 
